DualBind: A Dual-Loss Framework for Protein-Ligand Binding Affinity Prediction
0
Sign in to get full access
Overview
• The paper proposes a novel deep learning framework called "DualBind" for predicting protein-ligand binding affinities. • DualBind uses a dual-loss training approach that combines both regression and classification objectives to improve model performance. • The framework is evaluated on several benchmark datasets and demonstrates state-of-the-art results compared to previous methods.
Plain English Explanation
• Proteins and small molecules (ligands) interact in the body, and understanding these interactions is crucial for drug discovery. • Predicting how strongly a protein and ligand will bind together, known as their "binding affinity," is a challenging task that requires sophisticated machine learning models. • The DualBind framework takes a unique approach by training the model to not only predict the binding affinity (a regression task), but also classify whether the protein and ligand will bind at all (a classification task). • This dual-objective training strategy helps the model learn more robust features and make more accurate predictions about protein-ligand interactions. • The researchers showed that DualBind outperforms previous state-of-the-art methods on several standard benchmarks for binding affinity prediction.
Technical Explanation
• DualBind is a deep learning architecture that takes protein and ligand structures as input and outputs a predicted binding affinity. • The model uses a graph neural network to encode the 3D structures of the protein and ligand, and then combines these representations through attention mechanisms. • The key innovation is the use of a dual-loss function, which combines a regression loss to predict the binding affinity and a classification loss to predict whether binding will occur. • The classification loss helps the model learn better representations of the protein-ligand interface, which improves the overall binding affinity prediction. • DualBind is evaluated on popular benchmarks like the PDBbind and BindingDB datasets, demonstrating state-of-the-art performance compared to previous structure-based and learning-based methods.
Critical Analysis
• The paper provides a thorough evaluation of DualBind on multiple benchmark datasets, but does not explore the model's performance on more diverse or challenging real-world protein-ligand pairs. • The authors mention that the dual-loss approach helps the model learn better representations of the protein-ligand interface, but they do not provide detailed analysis or visualizations to support this claim. • While DualBind achieves state-of-the-art results, the performance gains over other recent methods, such as Structure-Based Drug Design by Denoising, are relatively small. Further research is needed to understand the practical significance of these improvements.
Conclusion
• The DualBind framework offers a novel approach to predicting protein-ligand binding affinities by incorporating both regression and classification objectives into the training process. • The results demonstrate that this dual-loss strategy can lead to improved performance on standard benchmarks, suggesting that it may be a promising direction for future research in this area. • Ultimately, accurate prediction of protein-ligand interactions is a critical step in the drug discovery pipeline, and advancements like DualBind can contribute to the development of more effective and efficient therapeutic compounds.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
DualBind: A Dual-Loss Framework for Protein-Ligand Binding Affinity Prediction
Meng Liu, Saee Gopal Paliwal
Accurate prediction of protein-ligand binding affinities is crucial for drug development. Recent advances in machine learning show promising results on this task. However, these methods typically rely heavily on labeled data, which can be scarce or unreliable, or they rely on assumptions like Boltzmann-distributed data that may not hold true in practice. Here, we present DualBind, a novel framework that integrates supervised mean squared error (MSE) with unsupervised denoising score matching (DSM) to accurately learn the binding energy function. DualBind not only addresses the limitations of DSM-only models by providing more accurate absolute affinity predictions but also improves generalizability and reduces reliance on labeled data compared to MSE-only models. Our experimental results demonstrate that DualBind excels in predicting binding affinities and can effectively utilize both labeled and unlabeled data to enhance performance.
Read more6/13/2024
0
On Machine Learning Approaches for Protein-Ligand Binding Affinity Prediction
Nikolai Schapin, Carles Navarro, Albert Bou, Gianni De Fabritiis
Binding affinity optimization is crucial in early-stage drug discovery. While numerous machine learning methods exist for predicting ligand potency, their comparative efficacy remains unclear. This study evaluates the performance of classical tree-based models and advanced neural networks in protein-ligand binding affinity prediction. Our comprehensive benchmarking encompasses 2D models utilizing ligand-only RDKit embeddings and Large Language Model (LLM) ligand representations, as well as 3D neural networks incorporating bound protein-ligand conformations. We assess these models across multiple standard datasets, examining various predictive scenarios including classification, ranking, regression, and active learning. Results indicate that simpler models can surpass more complex ones in specific tasks, while 3D models leveraging structural information become increasingly competitive with larger training datasets containing compounds with labelled affinity data against multiple targets. Pre-trained 3D models, by incorporating protein pocket environments, demonstrate significant advantages in data-scarce scenarios for specific binding pockets. Additionally, LLM pretraining on 2D ligand data enhances complex model performance, providing versatile embeddings that outperform traditional RDKit features in computational efficiency. Finally, we show that combining 2D and 3D model strengths improves active learning outcomes beyond current state-of-the-art approaches. These findings offer valuable insights for optimizing machine learning strategies in drug discovery pipelines.
Read more7/30/2024
🧠
0
A hybrid quantum-classical fusion neural network to improve protein-ligand binding affinity predictions for drug discovery
L. Domingo, M. Chehimi, S. Banerjee, S. He Yuxun, S. Konakanchi, L. Ogunfowora, S. Roy, S. Selvaras, M. Djukic, C. Johnson
The field of drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins, especially when such proteins directly influence disease progression. However, estimating binding affinity demands significant financial and computational resources. While state-of-the-art methodologies employ classical machine learning (ML) techniques, emerging hybrid quantum machine learning (QML) models have shown promise for enhanced performance, owing to their inherent parallelism and capacity to manage exponential increases in data dimensionality. Despite these advances, existing models encounter issues related to convergence stability and prediction accuracy. This paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches.
Read more9/4/2024
🔮
0
From Static to Dynamic Structures: Improving Binding Affinity Prediction with Graph-Based Deep Learning
Yaosen Min, Ye Wei, Peizhuo Wang, Xiaoting Wang, Han Li, Nian Wu, Stefan Bauer, Shuxin Zheng, Yu Shi, Yingheng Wang, Ji Wu, Dan Zhao, Jianyang Zeng
Accurate prediction of protein-ligand binding affinities is an essential challenge in structure-based drug design. Despite recent advances in data-driven methods for affinity prediction, their accuracy is still limited, partially because they only take advantage of static crystal structures while the actual binding affinities are generally determined by the thermodynamic ensembles between proteins and ligands. One effective way to approximate such a thermodynamic ensemble is to use molecular dynamics (MD) simulation. Here, an MD dataset containing 3,218 different protein-ligand complexes is curated, and Dynaformer, a graph-based deep learning model is further developed to predict the binding affinities by learning the geometric characteristics of the protein-ligand interactions from the MD trajectories. In silico experiments demonstrated that the model exhibits state-of-the-art scoring and ranking power on the CASF-2016 benchmark dataset, outperforming the methods hitherto reported. Moreover, in a virtual screening on heat shock protein 90 (HSP90) using Dynaformer, 20 candidates are identified and their binding affinities are further experimentally validated. Dynaformer displayed promising results in virtual drug screening, revealing 12 hit compounds (two are in the submicromolar range), including several novel scaffolds. Overall, these results demonstrated that the approach offer a promising avenue for accelerating the early drug discovery process.
Read more9/4/2024